Federal Register Notices
View Federal Register notices of proposed exclusive licenses. Clicking on the "View" links will display the Federal Register Notice in a new tab. You can also search directly on the Federal Register site.
| View | Date Published | Title | Comments Close On | Dates |
|---|---|---|---|---|
| View | National Cancer Institute; Grants and Cooperative Agreements Availability | Inquiries regarding CRADA proposals and scientific matters may be forwarded at any time. Confidential CRADA proposals, preferably two pages or less, must be submitted to the NCI on or before May 3, 1999. Guidelines for preparing full CRADA proposals will be communicated shortly thereafter to all respondents who have been selected. | ||
| View | Government-Owned Inventions; Availability for Licensing | |||
| View | Prospective Grant of Exclusive License: Conjugate Vaccines To Prevent Disease Caused by Nontypeable Haemophilus influenzae and Moraxella catarrahalis, Particularly Otitis Media | Only written comments and/or application for a license which are received by the NIH Office of Technology Transfer on or before May 4, 1999. | ||
| View | Government-Owned Inventions; Availability for Licensing | |||
| View | Government-Owned Inventions; Availability for Licensing | |||
| View | Government-Owned Inventions; Availability for Licensing | |||
| View | Government-Owned Inventions; Availability for Licensing | |||
| View | Prospective Grant of Exclusive License: Transformation Associated Recombination (TAR) System in Yeast for Specific Cloning of DNAs as Yeast Artificial Chromosomes (YACs) | Only written comments and/or application for a license which are received by the NIH Office of Technology Transfer on or before May 24, 1999 will be considered. | ||
| View | Government-Owned Inventions; Availability for Licensing | |||
| View | Prospective Grant of Exclusive License: ``Ultra Thin Walled Wire Reinforced Endotracheal Tubing'' | Only written comments and/or application for a license which are received by the NIH Office of Technology Transfer on or before March 29, 1999 will be considered. | ||
| View | Prospective Grant of Co-Exclusive License: erbB-2/HER2/neu Gene Segments, Probes, Recombinant DNA and Kits for Detection | Only written comments and/or application for a license which are received by the NIH Office of Technology Transfer on or before March 23, 1999 will be considered. | ||
| View | Licensing Opportunity and/or Cooperative Research and Development Agreement (``CRADA'') Opportunity: Drug And Method For The Therapeutic Treatment of Lymphomas And Leukemias | Respondees interested in licensing the invention(s) will be required to submit an ``Application for License to Public Health Service Inventions'' on or before March 1, 1999. | ||
| View | Prospective Grant of Exclusive License: Drug and Method for the Therapeutic Treatment of Ovarian Cancer and Mesotheliomas | Only written comments and/or applications for a license which are received by NIH on or before March 1, 1999, will be considered. | ||
| View | Government-Owned Inventions; Availability for Licensing: Drug and Method for the Therapeutic Treatment of Primary Brain Tumors (Such as Intracranial Human Glioma, Astrocytomas, Medulloblastomas and Metastatic Tumors to the Central Nervous System) | |||
| View | Prospective Grant of Exclusive License: Long-Acting Testosterone Androgenic Compounds and Pharmaceutical Compositions Thereof | Only written comments and/or application for a license which are received by the NIH Office of Technology Transfer on or before January 12, 1999, will be considered. | ||
| View | Licensing Opportunity and/or Cooperative Research and Development Agreement (``CRADA'') Opportunity: Drug and Method for the Therapeutic Treatment of Leukemia, Lymphoma, Hairy Cell Leukemia, Hodgkin's Disease, and Other Hematologic Malignancies | Respondees interested in licensing the invention(s) will be required to submit an ``Application for License to Public Health Service Inventions'' on or before January 8, 1999 for priority consideration. | ||
| View | National Cancer Institute: Opportunities for Cooperative Research and Development Agreements (CRADAs) for the Joint Evaluation and Development of Methods to Generate and Expand In-Vitro Modified Dendritic Cell Populations in Order to Elicit Phenotype Specific Immune Responses | Confidential CRADA statements of interest describing the proposed research, preferably one page or less, must be submitted to NCI on or before December 29, 1998. Guidelines for preparing full CRADA proposals will be communicated shortly thereafter to all respondents who have been selected on the basis of mutual scientific interest. | ||
| View | Prospective Grant of Exclusive License: Human Immunodeficiency Virus (HIV) ENV-Coded Peptide Capable of Eliciting HIV-Inhibiting Antibodies in Mammals | Only written comments and/or application for a license which are received by the NIH Office of Technology Transfer on or before January 28, 1999 will be considered. | ||
| View | Notice of Opportunities for Cooperative Research and Development Agreements | Organizations must submit a proposal summary preferably one page or less, to NCI within two weeks from date of this publication. Guidelines for preparing full CRADA proposals will be communicated shortly thereafter to all respondents with whom initial discussions will have established sufficient mutual interest. | ||
| View | National Cancer Institute; Opportunities for Cooperative Research and Development Agreements | In view of the high interest for developing the Technology, interested parties should notify the NCI Technology Development and Commercialization Branch in writing no later than November 18, 1998. Respondents will then be provided an additional thirty (30) days for submitting formal CRADA proposals. | ||
| View | Prospective Grant of Co-Exclusive License: erbB-2/HER2/neu Gene Segments, Probes, Recombinant DNA and Kits for Detection | Only written comments and/or application for a license which are received by the NIH Office of Technology Transfer on or before December 18, 1998 will be considered. | ||
| View | Prospective Grant of Exclusive License: 21 Substituted Progesterone Derivatives as New Anti-Progestational Agents | Only written comments and/or application for a license which are received by the NIH Office of Technology Transfer on or before December 18, 1998 will be considered. | ||
| View | National Cancer Institute: Opportunities for Cooperative Research and Development Agreements (CRADAs) for the Development and Evaluation of Chemokine or Chemokine Receptor Neutralizing Antibodies for Their Anti-Angiogenic Effects and Potential as Treatments for Cancer | Organizations must submit a confidential proposal summary preferably one page or less, to NCI on or before September 29, 1998. Guidelines for preparing full CRADA proposals will be communicated shortly thereafter to all respondents with whom initial confidential discussions will have established sufficient mutual interest. | ||
| View | Publication of the OIG Compliance Program Guidance for Home Health Agencies | |||
| View | Licensing Opportunity and/or Cooperative Research and Development Agreement (``CRADA'') Opportunity: Drug and Method To Prevent and Treat Graft-Versus-Host Disease and Allograft Rejection | Respondees interested in licensing the invention(s) will be required to submit an ``Application for License to Public Health Service Inventions'' on or before September 21, 1998 for priority consideration. |